Iambic Therapeutics Insider Trades
NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 1 · $11.50M
- Sales
- 0 · $0
- Shares bought / sold
- 718.75K / 0
- Net activity
- Net buying $11.5 million
Iambic Therapeutics insider activity
Over the last 12 months, Iambic Therapeutics insiders reported 18 transactions on SEC Form 4: 1 open-market purchase and 0 sales. Insiders bought $11.5 million and sold $0 worth of stock, for net insider buying of $11.5 million. The most recent filing shows RASTETTER WILLIAM H (Director) reporting a transaction in 192,579 shares on Oct 16, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put IAM's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
IAM insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 16, 2026 | Catalio Capital Management, LP & Catalio Nexus Fund III, LP & Catalio Access Fund VIII, LLC & Catalio BH SPV, LLC & Petrocheilos George C10% Owner | Conversion | 742,546 | — | Form 4 |
| Oct 16, 2026 | Catalio Capital Management, LP & Catalio Nexus Fund III, LP & Catalio Access Fund VIII, LLC & Catalio BH SPV, LLC & Petrocheilos George C10% Owner | Conversion | 1,458,290 | — | Form 4 |
| Oct 16, 2026 | Catalio Capital Management, LP & Catalio Nexus Fund III, LP & Catalio Access Fund VIII, LLC & Catalio BH SPV, LLC & Petrocheilos George C10% Owner | Conversion | 1,995,749 | — | Form 4 |
| Oct 16, 2026 | Secora MichaelCFO & Chief Corp Dev Ofcr | Conversion | 61,342 | — | Form 4 |
| Oct 16, 2026 | Vogelstein R JacobDirector | Conversion | 742,546 | — | Form 4 |
| Oct 16, 2026 | Vogelstein R JacobDirector | Conversion | 1,458,290 | — | Form 4 |
| Oct 16, 2026 | Vogelstein R JacobDirector | Conversion | 1,995,749 | — | Form 4 |
| Oct 16, 2026 | Rachlin Evan LockwoodDirector | Conversion | 57,754 | — | Form 4 |
| Oct 16, 2026 | Rachlin Evan LockwoodDirector | Buy | 718,750 | $11.50M | Form 4 |
| Oct 16, 2026 | Rachlin Evan LockwoodDirector | Conversion | 410,762 | — | Form 4 |
| Oct 16, 2026 | Rachlin Evan LockwoodDirector | Conversion | 1,458,736 | — | Form 4 |
| Oct 16, 2026 | RASTETTER WILLIAM HDirector | Conversion | 8,341 | — | Form 4 |
| Oct 16, 2026 | RASTETTER WILLIAM HDirector | Conversion | 192,579 | — | Form 4 |
| Oct 14, 2026 | Manby Frederick RChief Technology Officer | Award | 132,200 | — | Form 4 |
| Oct 14, 2026 | Josephson NeilChief Medical Officer | Award | 31,000 | — | Form 4 |
| Oct 14, 2026 | Olson Peter AChief Scientific Officer | Award | 19,500 | — | Form 4 |
| Oct 14, 2026 | Secora MichaelCFO & Chief Corp Dev Ofcr | Award | 28,400 | — | Form 4 |
| Oct 14, 2026 | Miller Thomas F.Chief Executive Officer | Award | 132,200 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4